Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

YOU WONT BELIEVE: Moderna s q4 2025 earnings what to expect - You Need To See This

Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $15.9 billion by market cap. The pharmaceutical and biotechnology company is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. 

Ahead of the event, analysts expect MRNA to report a loss of $2.79 per share on a diluted basis, down 11.6% from $2.50 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s bottom-line estimates in its last four quarterly reports. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.